Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients With Hypercholesterolemia

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lerodalcibep (Primary)
Indications Hypercholesterolaemia
Focus Therapeutic Use
Sponsors Hasten Biopharmaceutic

Most Recent Events

17 Dec 2025 According to a Everest Medicines media release, in Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.
17 Dec 2025 Primary endpoint has been met. (LDL-C change compared to Placebo), according to a Everest Medicines media release.
06 Feb 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com